Ligand-induced changes in cAMP concentration vary in duration, amplitude and extension into the cell. cAMP microdomains are shaped by adenylate cyclases that form cAMP as well as PDEs (phosphodiesterases) that degrade cAMP. Various extracellular signals converge on the cAMP/PKA (protein kinase A) pathway through ligand binding to GPCRs (G-protein-coupled receptors) and the cAMP/PKA pathway is therefore tightly regulated on several levels to maintain specificity in the multitude of signal inputs. AKAPs (A-kinaseanchoring proteins) target PKA to specific substrates and distinct subcellular compartments, providing spatial and temporal specificity for mediation of biological effects channelled through the cAMP/PKA pathway. AKAPs also serve as scaffolding proteins that assemble PKA together with signal terminators such as phosphoprotein phosphatases and cAMP-specific PDEs as well as components of other signalling pathways into multiprotein signalling complexes.
Introduction
cAMP activates Epac (exchange protein directly activated by cAMP) [1] , cAMP-regulated ion channels [2] and, last but not least, the broad-substrate-specificity enzyme PKA (protein kinase A) (reviewed in [3] ). The only known mechanism for inactivation of cAMP is through degradation by a large family of cAMP-specific PDEs [4, 5] . Compartmentalization of receptors, cyclases and PKA by AKAPs (A-kinase-anchoring proteins) [6] , as well as generation of local pools of cAMP within the cell by the action of PDEs [7] , generates a high degree of specificity in PKAmediated signalling, despite the broad substrate specificity of PKA. AKAPs contribute specificity by targeting PKA towards specific substrates, as well as versatility by assembling multiprotein signal complexes and allowing signal termination by phosphoprotein phosphatases and cross-talk between different signalling pathways [3, 8] . Integrating PDEs into these anchoring complexes adds a further temporal aspect to the spatial regulation of cAMP signals (reviewed in [9] ).
Localized pools of cAMP
cAMP microdomains are shaped by PDEs and differ in amplitude as well as spatiotemporal dynamics. It is feasible that a cAMP gradient elicited by a distinct ligand is specifically organized to follow a distinct route of PKA signalling by reaching and activating a subset of, or even a single, PKA-AKAP complex(es) to mediate a biological effect. The concept of localized Ca 2+ gradients and spikes is well established and they are generated by controlled release and re-uptake mechanisms [10] . Similarly, local domains of cAMP with discrete spatiotemporal organization are generated in response to external ligands [11] . PDEs contribute to the establishment of local gradients of cyclic nucleotides by being localized to subcellular compartments and by being recruited into multiprotein signalling complexes ( Figure 1 ). This contributes to the temporal and spatial specificity of cyclic nucleotide signalling by regulating the availability of cAMP/cGMP to their effectors as seen, e.g., in cardiomyocytes by FRET (fluorescence resonance energy transfer) imaging techniques [12] .
The distribution of PDEs to different subcellular localizations was proposed early on by the observation that PDE activity was found in both the soluble and particulate fractions of the cell [13] . Recent evidence further supports this notion and contributes to an emerging concept of a highly organized signal pathway where specific routes of cAMP signals are formed through the localized synthesis by cell-and tissue-specific adenylate cyclases. The signal is delivered to targeted effectors and terminated in a spatially and temporally defined manner by specific PDEs, establishing local pools of cAMP close to the effector molecules.
PKA anchoring
PKA is a heterotetramer composed of two regulatory and two catalytic subunits. Both the regulatory (RIα, RIβ, RIIα, RIIβ) and the catalytic (Cα, Cβ, Cγ ) subunits possess distinct physical and biological properties, are differentially expressed and are able to form different isoforms of PKA holoenzymes (reviewed in [3] ). Subcellular localization of PKA is mainly due to anchoring of the R subunits by AKAPs which originally were seen as contaminants of purified PKA [14] and later The local concentration and distribution of the cAMP gradient is limited by PDEs. Particular GPCRs are confined to specific domains of the cell membrane in association with intracellular organelles or cytoskeletal constituents. The subcellular structures may harbour specific isoenzymes of PKA that, through anchoring via AKAPs, are localized in the vicinity of the receptor and the cyclase. PDEs are also anchored and serve to limit the extension and duration of cAMP gradients. These mechanisms serve to localize and limit the assembly and triggering of specific pathways to a defined area of the cell close to the substrate.
understood to enhance the efficiency and specificity of the signalling events. PKA type I is classically known to be largely in the soluble fraction and was thus assumed to be mainly cytoplasmic. PKA type II is typically particulate and confined to subcellular structures and compartments anchored by cell-and tissue-specific AKAPs, a field largely pioneered by the Scott and Rubin laboratories (reviewed in [6, 15, 16] ). However, a few D-AKAPs (dual-specific AKAPs) that anchor both type I and type II PKAs, as well as some AKAPs that selectively bind type I PKA, have been identified more recently ( Table 1) .
As is evident from earlier NMR work and the recent elucidation of crystal structures of RII-AKAP complexes, the RII subunits dimerize at the N-terminus in an antiparallel fashion forming an X-type four-helix bundle which is necessary for both AKAP binding (N-terminal helix of both protomers) and dimerization (C-terminal helices of the bundle) through separate but overlapping regions involved in the two events [17] [18] [19] [20] . Dimerization is a prerequisite for AKAP binding; however, deletion of residues 1-5 in RII abolishes AKAP binding without disrupting dimer formation. Branched side chains at positions 3 and 5 are critical for the interaction with the AKAPs in a hydrophobic groove which is formed on top of the N-terminal helices [21, 22] . The RI dimerization domain contains a similar helix-turn-helix motif solved by NMR which is shifted a little further from the N-terminus and encompasses amino acids 12-61 [23] [24] [25] . The extreme N-terminus in RI is helical and believed to fold back on to the four-helix bundle and may thus contribute to differences in AKAP-binding specificity between RII and RI.
AKAPs
The intracellular targeting and compartmentalization of PKA is controlled through association with AKAPs. AKAPs are a structurally diverse family of functionally related proteins that now include more than 50 members when splice variants are included (Table 1) . They are defined on the basis of their ability to bind to PKA and co-precipitate catalytic activity. However, the functional importance further involves targeting the enzyme to specific subcellular compartments, thereby providing spatial and temporal regulation of the PKA signalling events. All anchoring proteins contain a PKAbinding domain and a unique targeting domain directing the PKA-AKAP complex to defined subcellular structures, membranes or organelles. In addition to these two domains, several AKAPs are also able to form multivalent signal transduction complexes by interaction with phosphoprotein phosphatases as well as other kinases and proteins involved in signal transduction. Through this essential role in the spatial and temporal integration of effectors and substrates, AKAPs provide a high level of specificity and temporal regulation to the cAMP/PKA signalling pathway.
Direct interaction between PDE and several different AKAPs has also been reported. AKAP450 targets PDE4D3 to the centrosomal region together with PKA type II in a ternary complex [26] . This was later verified using dominantnegative PDEs and showed that both PDE4D2 and PDE4C2 could bind to AKAP450 [27] . In cardiomyocytes, mAKAP (muscle-specific AKAP) binds and targets both PDE4D3 and PKA type II to the perinuclear region [28] . These were the first examples of co-localized PKA-PDE complexes providing spatial control of PKA signalling by AKAP anchoring and temporal control and termination of the cAMP signalling event by complexing PDE in the immediate vicinity. Furthermore, long PDE4 isoforms such as the PDE4D3 bound to AKAPs are activated by PKA phosphorylation [29, 30] . Thus the anchoring of both PKA and PDE in the same complex organized by AKAP serves to effectively establish a negative-feedback loop that terminates the cAMP signal locally (Figure 2 ). More recently, the cAMP-specific PDE7A isoform has also been shown to associate with several AKAPs (Table 1) , thus expanding the number of PDE-AKAP complexes and the spectrum of PDE isoforms that can associate with AKAPs.
Delineation of PKA type I-and type IImediated effects using PKA-anchoring disruptors
A prototypic tool to establish a functional role for various AKAPs has been the anchoring disruptor peptide Ht31, originally developed by the Scott laboratory on the basis of A similar mechanism operates in cardiomyocytes, where mAKAP binds and targets both PDE4D3 and PKA type II to the perinuclear region. Co-localized PKA and PDE provide spatial control of PKA signalling via anchoring to the same AKAP as well as temporal control and termination of cAMP signalling by a sequence of events that involve the following: (i) The effect of cAMP is mediated by PKA phosphorylation of substrate proteins; (ii) PKA phosphorylates and activates the PDE4D3 (PDE4D3 and other long PDE4 isoforms are PKA substrate, and phosphorylation leads to enhanced PDE activity); (iii) The co-localized and now activated PDE4D3 degrades cAMP and terminates the signal. This serves to establish a negative-feedback mechanism.
the α-helical amphipathic PKA-binding site in AKAPs [31] . By intracellular delivery through microinjection, liposomemediated delivery, use of stearated peptides or, more recently, through tagging with poly-arginine, Ht31 was used to displace PKA from its anchored sites and hence assess the effect of anchoring to AKAPs. Although Ht31 had low nanomolar affinity for RII, it also bound RI with sub-micromolar affinity [32] . By the use of two-dimensional peptide arrays, higher affinity anchoring disruptors such as AKAP-is (AKAP in silico) and a peptide designed for D-AKAPs were next developed [33, 34] . Recently, a third generation of anchoring disruptors were generated by use of parallel two-dimensional peptide arrays examining both RI and RII binding. Several rounds of substitutions selecting for RI and RII specificity led to development of the RI anchoring disruptor, RIAD, and super-AKAP-is with three orders of magnitude selectivity for RI and RII respectively [19, 35] . Next, RIAD could be used to implicate a PKA type I AKAP in cAMP immunomodulation through the cAMP/PKA/Csk inhibitory pathway we had mapped out earlier [35, 36] . We were also able to demonstrate that it is PKA type I that mediates cAMP regulation of steroidogenesis through control of cholesterol transport into mitochondria, probably via anchoring to Pap7 [35, 37] .
Signal complexes organized by AKAPs
The highest level of specificity and complexity in cAMP/PKA signalling is accomplished by the assembly of multiprotein complexes by AKAPs. Several AKAPs with this property have been identified that provide precise spatiotemporal regulation of the cAMP/PKA pathway and integration with other signalling pathways in one signal complex. AKAP79, AKAP450, AKAP220, gravin, WAVE [WASP (WiskottAldrich syndrome protein) verprolin homologous protein], AKAP-Lbc and mAKAP have all been shown to scaffold signalling complexes, and it is likely that we are still at the very beginning of understanding the roles AKAPs play in the orchestration of intracellular signalling events in health and disease (for references and recent reviews see [3, 6, 8, 9, 16] ).
In addition to its role in anchoring RII, studies of AKAP79 have contributed to the evolution of the model of AKAPs as multiprotein scaffolding proteins able to bind and anchor multiple signal transduction proteins and also regulate their enzymatic function. Although originally discovered as proteins able to bind and anchor PKA, the capacity of AKAP79 to associate with other signalling enzymes has led to an extension of the original AKAP model. By co-ordinating the location of PKC and the Ca 2+ /calmodulin-dependent phosphoprotein phosphatase PP2B (calcineurin) in addition to PKA, AKAP79 positions two second-messenger-regulated kinases and a phosphatase near neuronal substrates at the postsynaptic densities [38, 39] . Using an elegant experimental system that combined siRNA (small interfering RNA)-mediated knockdown of AKAP79 with overexpression of siRNA-resistant mutant versions of the AKAP, selection of transfected cells and cAMP imaging using FRET reporters, Hoshi et al. [40] could show that AKAP79 co-ordinates different combinations of anchored enzymes to modulate distinct signal pathways from two distinct receptors (bradykinin and muscarinic receptors) to two different effector systems, in this case two neuronal ion channels.
In a recent report, another signal complex involving mAKAP, PKA, PDE4D3, Epac and a MEKK/MEK5/ERK5 (where ERK is extracellular-signal-regulated kinase, MEK is mitogen-activated protein kinase/ERK kinase and MEKK is MEK kinase) module was described [41] . While mAKAP targets the complex and serves as an anchoring protein for PKA and PDE4D3, PDE4D3 serves as an adaptor for Epac and ERK5 and acts as a scaffold to co-ordinate a MEKK/ MEK5/ERK5 module [41] . In this model, ERK phosphorylation inhibits PDE4D3 [42] and thus serves to increase local cAMP. This in turn activates PKA, which phosphorylates PDE4D3 at a different site to increase both its activity [29, 30] and affinity for mAKAP [43] . This leads to decreased cAMP concentrations with a small time delay. At peak levels of cAMP, Epac1 [1] , a cAMP-stimulated guanine exchange protein, is also triggered and activates the small Ras-like GTPase Rap-1 [44] . Rap-1 then in turn inhibits MEKK and thus releases inhibition of PDE4D3 by ERK5 [41] . However, as the cAMP level decreases, ERK5 activity is prominent once again, leading to inhibition of PDE to allow for a new peak of cAMP. Using FRET reporters, the AKAP/PKA/PDE signalling unit has been observed to generate local pulses of cAMP [41] ; this is probably due to the different thresholds for activation of PKA (K act 100-400 nM) and PDE4D3 (K m 1-4 µM) as well as the time delay in PDE activation (Figure 3 ) [12] . This is particularly relevant for the mAKAP signal complex that coordinates three cAMP-responsive signalling molecules and where the Epac pathway (K d 4 µM) would activate only at peak cAMP concentrations. The configuration organized through scaffolding by mAKAP and PDE4D3 itself creates a spatially arranged signal complex with signal transduction molecules from several pathways that exploit the temporally regulated cAMP gradients by activating at different thresholds [41] .
Concluding remarks
Although a number of early studies indicated possibilities of compartmentalization of cAMP, the predominating view just a little more than a decade ago was still that cAMP would be elevated throughout the cell in response to many ligands. Detailed studies of compartmentalization of specific receptors and adenylate cyclases to distinct membrane subdomains, as well as live-cell imaging of cAMP and unravelling of the subcellular targeting of PDEs, has now made clear that physiological increases in cAMP occur in discrete microdomains. Similarly, although PKA type II was well known to be biochemically particulate and several AKAPs were known 10 years ago, the prevailing view was still that many effects of cAMP would be mediated by en bloc activation of PKA over large areas of the cell and/or that the C subunit would be released from a PKA holoenzyme complex and travel some distance to find its substrate. However, since then it has become clear that a large spectrum of AKAP proteins is available (more than 50 AKAPs to date when differentially targeted splice variants are included, Table 1 ). Furthermore, new AKAPs for PKA type I, long thought to be primarily cytoplasmic and freely diffusible, are now increasingly reported. In addition, the requirement for anchoring of PKA in order to regulate specific substrates as well as to mediate a number of physiological effects has been extensively studied over the last decade and, with few exceptions, it has been shown that most cAMP/PKA-regulated physiological processes require an anchored kinase. It has been made clear from studies discussed here that the localized cAMP microdomains require carefully compartmentalized and anchored pools of PDE enzymes. The concept described in this review that has emerged over the last 10-15 years, and which is now well established, is that a ligand normally will elicit a characteristic and local pool of cAMP that will follow a distinct route to reach and activate a single PKA-AKAP complex close to the substrate in order to mediate a distinct biological effect (Figure 1) . Accordingly, each substrate (or group of selected substrates) appears to have a restricted and anchored pool of PKA and its own local spatiotemporally organized gradient of cAMP limited by PDEs. Future studies are expected to identify a number of new anchoring proteins for the plethora of PDE enzymes and to increase our understanding of PDE regulation of the temporal aspect of localized cAMP pulses.
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